...
首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications
【24h】

Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications

机译:用于心血管应用的新型PEG官能化丙交酯共聚物生物材料的细胞织立性评价

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the two-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-?-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way towards surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic ( 2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5%±0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8°±2.3, PCL-PEG: 61.2°±7.5) versus those without (PLLA: 79.5°±3.2, PCL: 76.4°±10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent in vitro cyto- and hemocompatibility.
机译:尽管在支架生产中使用生物可吸收材料,但与他们的耐用对应物相比,近期FDA对第一个FDA批准的生殖血管支架的两年后随访的FDA报告显示了较近的主要发生与金属对照相比,不良心脏事件和血栓形成。为了克服第一代生物可吸收聚合物的问题,使用新的一步PEG官能化产生具有不同丙交酯 - 己内酯含量的一系列聚乙二醇官能化的聚-1-丙基丙交酯-CO - α - 己内酯共聚物和共聚策略。该方法代表了对细胞相互作用的表面增强的新的容易方式,这通过筛选这些材料在细胞毒性,溶血,血小板粘附,白细胞活化和内皮细胞粘附方面进行了关于它们的细胞和血液相位性。通过改变丙交酯 - 己内酯聚合物组合物,可以逐渐影响内皮和血小板粘附,这允许基于聚合物化学进行微调的生物响应。除了PLCL-PEG 55:45之外,所有开发的聚合物都具有非细胞毒性,具有可接受的白细胞活化水平并呈现非溶血(<2%溶血率)行为,其溶血率为2.5%±0.5。在含有PEG官能化的聚合物中降低了水接触角(PLLA-PEG:69.8°±2.3,PCL-PEG:61.2°±7.5),而不是(PLLA:79.5°±3.2,PCL:76.4°±10.2)材料PCL-PEG550,PLCL-PEG550 90:10和PLCL-PEG550 70:30显示最佳内皮细胞粘附。 PLLA-PEG550和PLCL-PEG550 70:30作为最佳候选人,用于在整个测试范围内的细胞势型视角下的心血管植入物使用。总的来说,这些聚合物是由于该一步合成策略对器件生产的易于翻译和它们优异的体外细胞和血液相位性而在支架制造中适用于支架制造的优异创新材料。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号